SRR1313100
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.430
- MYC_TARGETS_V1+0.410
- ESTROGEN_RESPONSE_EARLY+0.390
- MTORC1_SIGNALING+0.380
- E2F_TARGETS+0.340
- ADIPOGENESIS+0.300
- ANDROGEN_RESPONSE+0.290
- ESTROGEN_RESPONSE_LATE+0.280
- FATTY_ACID_METABOLISM+0.280
- UNFOLDED_PROTEIN_RESPONSE+0.280
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- ALLOGRAFT_REJECTION-0.410
- TNFA_SIGNALING_VIA_NFKB-0.330
- INTERFERON_GAMMA_RESPONSE-0.310
- COAGULATION-0.260
- INTERFERON_ALPHA_RESPONSE-0.260
- IL6_JAK_STAT3_SIGNALING-0.240
- MYOGENESIS-0.240
- HEDGEHOG_SIGNALING-0.230
- INFLAMMATORY_RESPONSE-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0WV-01A-11R-A109-07 | — | B | 0.888 |
| 2 | TCGA-A8-A06Z-01A-11R-A00Z-07 | — | B | 0.881 |
| 3 | DRR168570 | — | — | 0.870 |
| 4 | TCGA-A2-A25E-01A-11R-A169-07 | — | B | 0.865 |
| 5 | ULC0410T_S45 | — | cohortA4 | 0.860 |
| 6 | 9f6a2480-748d-414b-be0b-36be34c24037 | — | — | 0.856 |
| 7 | TCGA-HQ-A2OF-01A-11R-A26T-07 | — | — | 0.854 |
| 8 | SRR2932839 | — | — | 0.850 |
| 9 | TCGA-AR-A0U3-01A-11R-A109-07 | — | B | 0.849 |
| 10 | SRR12202419 | — | — | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.390 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.380 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.340 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.290 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.280 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.280 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.270 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.220 | Temsirolimus | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.120 | Remibrutinib | — uncovered |